These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34736794)

  • 1. Heavy mutagenesis by tobacco leads to lung adenocarcinoma tumors with KRAS G12 mutations other than G12D, leading KRAS G12D tumors-on average-to exhibit a lower mutation burden.
    Tan C; Mandell JD; Dasari K; Cannataro VL; Alfaro-Murillo JA; Townsend JP
    Lung Cancer; 2022 Apr; 166():265-269. PubMed ID: 34736794
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic value of KRAS G12V mutation in lung adenocarcinoma stratified by stages and radiological features.
    Zhu W; Han H; Ma Z; Cao H; Yan Y; Zhao Y; Deng C; Xu H; Fu F; Fan F; Zhang Y; Chen H
    J Thorac Cardiovasc Surg; 2024 Dec; 168(6):1525-1537.e6. PubMed ID: 38527651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study.
    Zhou Q; Meng X; Sun L; Huang D; Yang N; Yu Y; Zhao M; Zhuang W; Guo R; Hu Y; Pan Y; Shan J; Sun M; Yuan Y; Fan Y; Huang J; Liu L; Chu Q; Wang X; Xu C; Lin J; Huang J; Huang M; Sun J; Zhang S; Zhou H; Wu YL
    J Thorac Oncol; 2024 Dec; 19(12):1630-1639. PubMed ID: 39127176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic reprogramming by mutant GNAS creates an actionable dependency in intraductal papillary mucinous neoplasms of the pancreas.
    Makino Y; Rajapakshe KI; Chellakkan Selvanesan B; Okumura T; Date K; Dutta P; Abou-Elkacem L; Sagara A; Min J; Sans M; Yee N; Siemann MJ; Enriquez J; Smith P; Bhattacharya P; Kim M; Dede M; Hart T; Maitra A; Thege FI
    Gut; 2024 Dec; 74(1):75-88. PubMed ID: 39277181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of G12D mutation in the KRAS gene with HPV and EBV in gastrointestinal cancer tissues.
    Hamidi Sofiani V; Ebrahimian Shiadeh A; Tabarraei A; Nikoo HR; Sadeghi F; Kamrani G; Yahyapour Y; Moradi A
    J Int Med Res; 2024 Dec; 52(12):3000605241302302. PubMed ID: 39673361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma.
    Cao H; Ma Z; Huang Q; Han H; Li Y; Zhang Y; Chen H
    Eur J Cancer; 2024 May; 202():113985. PubMed ID: 38452722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.
    Gao G; Liao W; Ma Q; Zhang B; Chen Y; Wang Y
    Lung Cancer; 2020 Nov; 149():41-45. PubMed ID: 32956987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA variants detected in primary and metastatic lung adenocarcinoma: a case report and review of the literature.
    Kelly C; Raymond C; Han S; Lin Y; Chen L; Huang G; Dong J
    Lab Med; 2024 Sep; 55(5):658-662. PubMed ID: 38527227
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Gelfer R; Gulla A; Kalvin HL; Song Y; Harding J; Abou-Alfa GK; O'Reilly EM; Park W; Chandwani R; Wei A; Kingham P; Drebin J; Balachandran V; D'Angelica M; Soares K; Gonen M; Jarnagin WR
    JCO Precis Oncol; 2024 Dec; 8():e2400263. PubMed ID: 39642327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Syngeneic tobacco carcinogen-induced mouse lung adenocarcinoma model exhibits PD-L1 expression and high tumor mutational burden.
    Stabile LP; Kumar V; Gaither-Davis A; Huang EH; Vendetti FP; Devadassan P; Dacic S; Bao R; Steinman RA; Burns TF; Bakkenist CJ
    JCI Insight; 2021 Feb; 6(3):. PubMed ID: 33351788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of
    Chouaid C; Giannopoulou A; Starry A; Stollenwerk B; Bozorgmehr F
    J Med Econ; 2025 Dec; 28(1):13-24. PubMed ID: 39620475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment.
    Wang K; Xu M; Wang Y; Xu C; Hao Y; Song Z
    Clin Transl Oncol; 2024 Oct; 26(10):2479-2487. PubMed ID: 38625494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS mutations in endometrial cancers: Possible prognostic and treatment implications.
    Kilowski KA; Dietrich MF; Xiu J; Baca Y; Hinton A; Ahmad S; Herzog TJ; Thaker P; Holloway RW
    Gynecol Oncol; 2024 Dec; 191():299-306. PubMed ID: 39500247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid biopsy as a tool for KRAS/NRAS/BRAF baseline testing in metastatic colorectal cancer.
    Kourie HR; Zouein J; Zalaquett Z; Chebly A; Nasr L; Karak FE; Sadek M; Safar O; Fouani M; Bitar N; Kachmar K; Nasr F; Farhat F; Makarem J; Kattan J; Taieb J
    Clin Res Hepatol Gastroenterol; 2024 Oct; 48(8):102417. PubMed ID: 39009221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer.
    Tong X; Patel AS; Kim E; Li H; Chen Y; Li S; Liu S; Dilly J; Kapner KS; Zhang N; Xue Y; Hover L; Mukhopadhyay S; Sherman F; Myndzar K; Sahu P; Gao Y; Li F; Li F; Fang Z; Jin Y; Gao J; Shi M; Sinha S; Chen L; Chen Y; Kheoh T; Yang W; Yanai I; Moreira AL; Velcheti V; Neel BG; Hu L; Christensen JG; Olson P; Gao D; Zhang MQ; Aguirre AJ; Wong KK; Ji H
    Cancer Cell; 2024 Mar; 42(3):413-428.e7. PubMed ID: 38402609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Correlation between common driver gene variations and clinicopathological typing in lung adenocarcinoma].
    Ma XL; Jia RN; Han K; Zhang YX
    Zhonghua Bing Li Xue Za Zhi; 2024 Jun; 53(6):578-584. PubMed ID: 38825903
    [No Abstract]   [Full Text] [Related]  

  • 17. Peripheral lung adenocarcinomas with KRAS mutations are more likely to invade visceral pleura.
    Raparia K; Villa C; Raj R; Cagle PT
    Arch Pathol Lab Med; 2015 Feb; 139(2):189-93. PubMed ID: 24694341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel label-free impedance biosensor for KRAS G12C mutations detection based on PET-RAFT and ROP synergistic signal amplification.
    Zhang Y; Wei H; Guo L; Gao W; Cheng D; Liu Y
    Bioelectrochemistry; 2025 Feb; 161():108844. PubMed ID: 39531994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies.
    Liguori L; Salomone F; Viggiano A; Sabbatino F; Pepe S; Formisano L; Bianco R; Servetto A
    Crit Rev Oncol Hematol; 2025 Jan; 205():104554. PubMed ID: 39522850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical requirement of SOS1 for tumor development and microenvironment modulation in KRAS
    Baltanás FC; García-Navas R; Rodríguez-Ramos P; Calzada N; Cuesta C; Borrajo J; Fuentes-Mateos R; Olarte-San Juan A; Vidaña N; Castellano E; Santos E
    Nat Commun; 2023 Sep; 14(1):5856. PubMed ID: 37730692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.